Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form
As of April 1st VIVO Scientific Profiles will no longer updated for faculty, and the link to VIVO will be removed from the library website. Faculty profile pages will continue to be updated via Interfolio. VIVO will continue being used behind the scenes to update graduate student profiles. Please contact helplib@scripps.edu if you have questions.
How to download citations from VIVO | Alternative profile options

Bortezomib inhibits hepatitis B virus replication in transgenic mice

Academic Article
uri icon
  • Overview
  • Identity
  • Additional Document Info
  • View All
scroll to property group menus

Overview

authors

  • Bandi, P.
  • Garcia, M. L.
  • Booth, C. J.
  • Chisari, Francis
  • Robek, M. D.

publication date

  • February 2010

journal

  • Antimicrobial Agents and Chemotherapy  Journal

abstract

  • Pharmacological modulation of cellular proteins as a means to block virus replication has been proposed as an alternative antiviral strategy that may be less susceptible than others to the development of viral drug resistance. Recent evidence indicates that the ubiquitin-proteasome pathway interacts with different aspects of the hepatitis B virus (HBV) life cycle in cell culture models of virus replication. We therefore examined the effect of proteasome inhibition on HBV replication in vivo using HBV transgenic mice. The proteasome inhibitor bortezomib (Velcade) inhibits proteasome activity in vivo and is used therapeutically for the clinical treatment of multiple myeloma. We found that a single intravenous dose of 1 mg of bortezomib/kg of body weight reduced virus replication for as long as 6 days. The inhibition of HBV by bortezomib was dose dependent and occurred at a step in replication subsequent to viral RNA and protein expression. The reduction in HBV replication did not result from nonspecific hepatocellular toxicity and was not mediated indirectly through the induction of an intrahepatic interferon response. Thus, pharmacological manipulation of the ubiquitin-proteasome pathway may represent an alternative therapeutic approach for the treatment of chronic HBV infection.

subject areas

  • Animals
  • Antiviral Agents
  • Boronic Acids
  • Bortezomib
  • Cytokines
  • DNA, Viral
  • Hepatitis B
  • Hepatitis B Core Antigens
  • Hepatitis B Surface Antigens
  • Hepatitis B e Antigens
  • Hepatitis B virus
  • Immunohistochemistry
  • Liver
  • Mice
  • Mice, Transgenic
  • Pyrazines
  • Reverse Transcriptase Polymerase Chain Reaction
  • Virus Replication
scroll to property group menus

Identity

PubMed Central ID

  • PMC2812171

International Standard Serial Number (ISSN)

  • 0066-4804

Digital Object Identifier (DOI)

  • 10.1128/aac.01101-09

PubMed ID

  • 19949053
scroll to property group menus

Additional Document Info

start page

  • 749

end page

  • 756

volume

  • 54

issue

  • 2

©2022 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support